Identity
Other names: SEB HGNC (Hugo): SETBP1 Location: 18q12.3 Local order: From centromere to telomere: SETBP1, SMAD2, SMAD4, BCL2.
DNA/RNA
Description SETBP1 has two isoforms: transcript variant a spans 387,61 kb on the genomic DNA and has 6 exons; transcript variant b spans 197,24 kb on the genomic DNA and includes 4 exons. 
Protein

Description
Two isoforms: variant a (1596 amino acids); variant b (242 amino acids).
Expression
Expressed in numerous tissues.
Localisation
Predominantly in the nucleus (Minakuchi et al., 2001; Cristóbal et al., 2010) .
Function
SETBP1 overexpression promotes leukemogenesis by enhancing full-length SET protein and then impairing the phosphatase activity of the tumor suppressor PP2A in acute myeloid leukaemia. In addition, defects in SETBP1 have been described as the cause of SchinzelGiedion syndrome.
Homology
The protein contains a region homologous to the dimerization domain of the SKI oncoprotein, six PEST sequences, three AT-hook DNA binding domains, a SET-binding domain and three nuclear localization signals.
Mutations
Somatic
De novo mutations have been decribed in patients with Schinzel-Giedion syndrome: I871T (5 unrelated patients), D868N (4 unrelated patients), D868A (one case), G870D (one case) and G870S (three unrelated patients) (Hoischen et al., 2010; Suphapeetiporn et al., 2011) .
Implicated in
Pediatric T-cell acute lymphoblastic leukemia (T-ALL) (Panagopoulos et al., 2007)
Cytogenetics t(11;18)(p15;q12); only one case decribed so far. Cristóbal I, et al. Atlas Genet Cytogenet Oncol Haematol. 2013; 17(3) Hybrid/Mutated gene 5' NUP98 -3' SETBP1 Abnormal protein The NUP98-SETBP1 fusion protein consists in the exon 12 of NUP98 fused in-frame with exon 5 of SETBP1. Oncogenesis SETBP1/NUP98 expression was not detected, suggesting that the NUP98/SETBP1 transcript is pathogenetically important.
SETBP1 (SET binding protein 1)
Schinzel-Giedion syndrome
Prognosis Defects in SETBP1 caused by the presence of the novo mutations have been described as the cause of Schinzel-Giedion midface retraction syndrome. Cytogenetics Normal karyotype.
Acute myeloid leukemia (AML)
Prognosis SETBP1 overexpression associates with worse overall survival specially in the subgroup of elderly patients (older than 60 years). 
Cytogenetics
The presence of a t(12;18)(p13;q12) has been describe in one case with AML secondary to myelodysplastic syndrome (figure 1) (Cristóbal et al., 2010) , and in one case with AML secondary to primary myelofibrosis (Albano et al., 2012) . Oncogenesis SETBP1 overexpression promotes leukemogenesis by enhancing full-length SET protein and then impairing the phosphatase activity of the tumor suppressor PP2A through the formation of a SETBP1-SET-PP2A complex.
